F-star Therapeutics Profit Margin

F-star Therapeutics posts a profit margin of -212.48% as of September 2022. That compares with -1170.87% in the prior-year period — up 81.9% year over year. That is below the Healthcare sector average of 9.48%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, F-star Therapeutics's profit margin was -1170.87%. The latest reading is -212.48% — a 81.9% year-over-year increase (period ending September 2022). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 9.48% is typical. F-star Therapeutics's -212.48% is lower that level. That is roughly 2341.1% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

F-star Therapeutics's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -212.48% as of September 2022; use YoY and peer views to separate noise from signal.

Context for FSTX's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 9.48%), and (3) consistency with growth and profitability. This page covers the first two; F-star Therapeutics's other metric pages and overview cover the third.